Ascelia Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Selling, General & Admin	17.31	17.33	30.21	29.56	30.32	Upgrade
Research & Development	56.82	50.8	81.27	118.11	107.57	Upgrade
Other Operating Expenses	0.24	-	-0	-	-	Upgrade
Operating Expenses	74.37	68.12	111.48	147.67	137.9	Upgrade
Operating Income	-74.37	-68.12	-111.48	-147.67	-137.9	Upgrade
Interest Expense	-5.51	-3.71	-	-0.05	-0.08	Upgrade
Interest & Investment Income	3.16	0.77	1.32	0.64	0.01	Upgrade
Currency Exchange Gain (Loss)	-	0.54	0.55	13.93	8.44	Upgrade
Other Non Operating Income (Expenses)	-	-9.61	-	-0	-	Upgrade
EBT Excluding Unusual Items	-76.72	-80.12	-109.61	-133.16	-129.52	Upgrade
Pretax Income	-76.72	-80.12	-109.61	-133.16	-129.52	Upgrade
Income Tax Expense	-0.47	-0.09	-0.32	-1.93	-3.62	Upgrade
Net Income	-76.25	-80.03	-109.29	-131.22	-125.9	Upgrade
Net Income to Common	-76.25	-80.03	-109.29	-131.22	-125.9	Upgrade
Shares Outstanding (Basic)	113	54	34	35	33	Upgrade
Shares Outstanding (Diluted)	113	54	34	35	33	Upgrade
Shares Change (YoY)	110.07%	60.15%	-3.10%	5.58%	25.46%	Upgrade
EPS (Basic)	-0.67	-1.48	-3.24	-3.77	-3.82	Upgrade
EPS (Diluted)	-0.67	-1.48	-3.24	-3.77	-3.82	Upgrade
Free Cash Flow	-72.31	-62.84	-126.79	-125.26	-116.6	Upgrade
Free Cash Flow Per Share	-0.64	-1.16	-3.76	-3.60	-3.54	Upgrade
EBITDA	-74.3	-68.05	-111.4	-147.6	-137.8	Upgrade
D&A For EBITDA	0.07	0.07	0.07	0.07	0.1	Upgrade
EBIT	-74.37	-68.12	-111.48	-147.67	-137.9	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.